CPA4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14509143	0.46	7/20
SCHEMBL6824349	0.58	6/20
SCHEMBL6827926	0.58	6/20
SCHEMBL6827930	0.58	6/20
SCHEMBL6824195	0.57	6/20
SCHEMBL14542979	0.57	6/20
SCHEMBL7162400	0.45	6/20
SCHEMBL1642187	0.38	6/20
SCHEMBL7391699	0.64	5/20
SCHEMBL2632703	0.61	5/20
SCHEMBL2632695	0.62	4/20
SCHEMBL9697346	0.58	4/20
SCHEMBL8271877	0.51	4/20
SCHEMBL7497156	0.48	4/20
SCHEMBL7497160	0.48	4/20
SCHEMBL11228295	0.48	4/20
SCHEMBL10718337	0.47	4/20
SCHEMBL10716135	0.46	4/20
SCHEMBL7048091	0.43	4/20
SCHEMBL7047064	0.42	4/20

Clinical trials — most relevant to CPA4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Fluticasone and Salmeterol in Allergic Rhinitis	PHASE4	COMPLETED
Effects of Anti-TSLP in Patients With Asthma	PHASE2	COMPLETED
Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis	PHASE1/PHASE2	COMPLETED
Study of the Mechanisms of Asthma	PHASE1	COMPLETED
Chemokine Mechanisms in Chronic Pelvic Pain	nan	COMPLETED
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3	nan	COMPLETED
Markers in Acute Pancreatitis-1	nan	COMPLETED
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations	nan	COMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests	nan	UNKNOWN
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)	nan	UNKNOWN
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome	nan	WITHDRAWN
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
New Time Clock for ST-elevation MI Based on Biochemical Myocardial Infarction Onset Time	nan	UNKNOWN
Preventing Acute Chest Syndrome by Transfusion Feasibility Study	nan	COMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Cause and Natural Course of Pediatric-Onset Mastocytosis	nan	COMPLETED
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation	nan	COMPLETED
Allergy and Immunology Natural History Study	nan	RECRUITING
Pathogenesis of Physical Induced Urticarial Syndromes	nan	COMPLETED
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
Identification and Characterization of Genetic Variants in Hereditary Angioedema	nan	NOT_YET_RECRUITING
Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin	nan	COMPLETED
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin	nan	UNKNOWN
Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma	nan	UNKNOWN
Genomic Research in Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CPA4 binder may also engage these)

Protein	Name	Similarity
CPA2	Carboxypeptidase A2	1.000	landscape →
P09954	—	0.999	P09954 →
Q9JHH6	—	0.997	Q9JHH6 →
Q8WXQ8	—	0.995	Q8WXQ8 →
Q0II73	—	0.995	Q0II73 →
Q6P8K8	—	0.994	Q6P8K8 →
P19223	—	0.994	P19223 →
CPB1	Carboxypeptidase B	0.994	landscape →
P00732	—	0.994	P00732 →
P09955	—	0.993	P09955 →
B8JLQ9	—	0.993	B8JLQ9 →
Q9EQV9	—	0.992	Q9EQV9 →
Q3T905	—	0.992	Q3T905 →
O02350	—	0.992	O02350 →
D4D675	—	0.992	D4D675 →
P55261	—	0.991	P55261 →
P00730	—	0.991	P00730 →
Q504N0	—	0.990	Q504N0 →
P00731	—	0.990	P00731 →
CPA1	Carboxypeptidase A1	0.989	landscape →
D4DL57	—	0.989	D4DL57 →
Q9VL86	—	0.989	Q9VL86 →
Q2KIG3	—	0.989	Q2KIG3 →
A0A1S4F020	—	0.989	A0A1S4F020 →
Q4R7R2	—	0.988	Q4R7R2 →
B6V865	—	0.988	B6V865 →
Q8R4H4	—	0.988	Q8R4H4 →
Q7TPZ8	—	0.988	Q7TPZ8 →
CPA3	Mast cell carboxypeptidase A	0.988	landscape →
P19222	—	0.987	P19222 →